Advanced Search

    Technical Analysis for GLTO - Galecto, Inc.

    Grade Last Price % Change Price Change
    B 2.24 0.00% 0.00
    GLTO closed up 1.82 percent on Monday, January 30, 2023, on 51 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
    Earnings due: Feb 15
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical GLTO trend table...
    Date Alert Name Type % Chg
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Wide Bands Range Expansion 1.82%
    Overbought Stochastic Strength 1.82%
    Outside Day Range Expansion 9.27%
    Wide Bands Range Expansion 9.27%
    Overbought Stochastic Strength 9.27%
    Gapped Down Weakness 9.27%
    Older End-of-Day Signals for GLTO ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Down 5% 24 minutes ago
    Down 3% 24 minutes ago
    Fell Below Previous Day's Low 24 minutes ago
    Down 2 % 24 minutes ago
    Down 1% 24 minutes ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators Basic chart:

    Profile

    Galecto, Inc. Description

    Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Clinical Medicine Biology Alcohol Inflammation Steatohepatitis Non Alcoholic Fatty Liver Disease Breakthrough Therapy Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Progressive Fibrosis mTOR Fibrotic Disease Myelofibrosis Copenhagen Lectins Lung Diseases Treatment Of Fibrosis Galectin Galectin 3 Galecto Biotech Primary Myelofibrosis

    Is GLTO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Dec 11 Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?
    Dec 7 Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting
    Nov 24 Galecto, Inc. (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
    Nov 11 All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy
    Nov 8 Galecto GAAP EPS of -$0.54
    Nov 8 Galecto Reports Third Quarter Operating and Financial Results
    Nov 8 Galecto stock rises 12% as GB1211 shows efficacy in liver disease patients in trial
    Nov 8 Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients
    Nov 4 Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
    Nov 3 Galecto to Participate in Jefferies London Healthcare Conference
    See more GLTO news...

    Indicators

    Indicator Value
    52 Week High 2.8
    52 Week Low 1.04
    Average Volume 57,414
    200-Day Moving Average 1.81
    50-Day Moving Average 1.58
    20-Day Moving Average 1.83
    10-Day Moving Average 2.01
    Average True Range 0.18
    RSI 67.85
    ADX 18.84
    +DI 29.53
    -DI 16.46
    Chandelier Exit (Long, 3 ATRs) 1.74
    Chandelier Exit (Short, 3 ATRs) 1.59
    Upper Bollinger Bands 2.43
    Lower Bollinger Band 1.22
    Percent B (%b) 0.84
    BandWidth 66.12
    MACD Line 0.18
    MACD Signal Line 0.14
    MACD Histogram 0.0363
    Fundamentals Value
    Market Cap 55.07 Million
    Num Shares 24.6 Million
    EPS
    Price-to-Sales 0.00
    Price-to-Book 11.08
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.39
    Resistance 3 (R3) 2.38 2.33 2.37
    Resistance 2 (R2) 2.33 2.29 2.33 2.36
    Resistance 1 (R1) 2.28 2.26 2.31 2.29 2.35
    Pivot Point 2.23 2.23 2.24 2.23 2.23
    Support 1 (S1) 2.18 2.19 2.21 2.19 2.13
    Support 2 (S2) 2.13 2.16 2.13 2.12
    Support 3 (S3) 2.08 2.13 2.12
    Support 4 (S4) 2.09